
News|Articles|October 12, 2012
Resuming warfarin after GIB event decreases risk of thrombosis, death
Patients who experience a warfarin-associated gastrointestinal tract bleeding event should resume anticoagulation therapy during the 90 days following the event to decrease the risk of thrombosis and death, according to a study published online in the Archives of Internal Medicine.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
3
TrumpRx launches; some experts question its long-term value
4
Cancer survival fell and deaths rose during first two years of COVID-19
5























